Take Solutions Limited (TAKE) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.122x

Based on the latest financial reports, Take Solutions Limited (TAKE) has a cash flow conversion efficiency ratio of -0.122x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-31.39 Million ≈ $-339.47K USD) by net assets (Rs256.29 Million ≈ $2.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Take Solutions Limited (TAKE) liquidity interval to measure how many days the company can operate on defensive assets alone.

Take Solutions Limited - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Take Solutions Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Take Solutions Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Take Solutions Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
European Metals Holdings Ltd
AU:EMH
-0.036x
EM-Tech.CO. LTD
KQ:091120
0.018x
Changhae Ethanol Co. Ltd
KQ:004650
0.102x
Thomas Scott (India) Limited
NSE:THOMASCOTT
-0.146x
Airmate Cayman International Co Ltd
TW:1626
-0.074x
Kristal Kola ve Mesrubat Sanayi Ticaret AS
IS:KRSTL
0.061x
PB Bankshares Inc
NASDAQ:PBBK
0.015x
Europacorp
PA:ALECP
-1.972x

Annual Cash Flow Conversion Efficiency for Take Solutions Limited (2007–2025)

The table below shows the annual cash flow conversion efficiency of Take Solutions Limited from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see TAKE stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs205.27 Million
≈ $2.22 Million
Rs-163.66 Million
≈ $-1.77 Million
-0.797x +24.06%
2024-03-31 Rs-88.73 Million
≈ $-959.58K
Rs93.16 Million
≈ $1.01 Million
-1.050x -669.68%
2023-03-31 Rs1.09 Billion
≈ $11.74 Million
Rs200.16 Million
≈ $2.16 Million
0.184x +12.40%
2022-03-31 Rs1.81 Billion
≈ $19.53 Million
Rs296.17 Million
≈ $3.20 Million
0.164x +36.32%
2021-03-31 Rs11.24 Billion
≈ $121.59 Million
Rs1.35 Billion
≈ $14.63 Million
0.120x -9.68%
2020-03-31 Rs15.85 Billion
≈ $171.45 Million
Rs2.11 Billion
≈ $22.83 Million
0.133x +96.40%
2019-03-31 Rs15.27 Billion
≈ $165.18 Million
Rs1.04 Billion
≈ $11.20 Million
0.068x -25.00%
2018-03-31 Rs13.37 Billion
≈ $144.56 Million
Rs1.21 Billion
≈ $13.07 Million
0.090x +54.17%
2017-03-31 Rs9.53 Billion
≈ $103.08 Million
Rs558.98 Million
≈ $6.05 Million
0.059x -73.41%
2016-03-31 Rs6.72 Billion
≈ $72.62 Million
Rs1.48 Billion
≈ $16.02 Million
0.221x +72.74%
2015-03-31 Rs5.80 Billion
≈ $62.78 Million
Rs741.25 Million
≈ $8.02 Million
0.128x -33.69%
2014-03-31 Rs5.18 Billion
≈ $56.06 Million
Rs998.25 Million
≈ $10.80 Million
0.193x -23.03%
2013-03-31 Rs4.66 Billion
≈ $50.41 Million
Rs1.17 Billion
≈ $12.61 Million
0.250x -17.75%
2012-03-31 Rs3.80 Billion
≈ $41.05 Million
Rs1.15 Billion
≈ $12.49 Million
0.304x +45.36%
2011-03-31 Rs2.82 Billion
≈ $30.48 Million
Rs589.85 Million
≈ $6.38 Million
0.209x +341.83%
2010-03-31 Rs3.86 Billion
≈ $41.70 Million
Rs182.63 Million
≈ $1.98 Million
0.047x -72.58%
2009-03-31 Rs3.86 Billion
≈ $41.73 Million
Rs666.62 Million
≈ $7.21 Million
0.173x +1.88%
2008-03-31 Rs2.98 Billion
≈ $32.28 Million
Rs506.13 Million
≈ $5.47 Million
0.170x +25.11%
2007-03-31 Rs885.44 Million
≈ $9.58 Million
Rs120.02 Million
≈ $1.30 Million
0.136x --

About Take Solutions Limited

NSE:TAKE India Biotechnology
Market Cap
$47.06 Million
Rs4.35 Billion INR
Market Cap Rank
#22192 Global
#1231 in India
Share Price
Rs29.76
Change (1 day)
+0.34%
52-Week Range
Rs8.33 - Rs50.14
All Time High
Rs293.99
About

TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient c… Read more